Joanne Tsai is a seasoned analytics leader at Pfizer, where she serves as the Director of Data Science in Oncology. With over 15 years of experience in the healthcare sector, Joanne has developed a robust expertise that spans biopharmaceuticals, medical devices, and integrated delivery networks....
Joanne Tsai is a seasoned analytics leader at Pfizer, where she serves as the Director of Data Science in Oncology. With over 15 years of experience in the healthcare sector, Joanne has developed a robust expertise that spans biopharmaceuticals, medical devices, and integrated delivery networks. Her current role involves overseeing critical portfolios, including Breast Cancer treatments like Ibrance and Talzenna, as well as therapies for colorectal cancer and melanoma such as Braftovi and Mektovi, and non-small cell lung cancer (NSCLC) treatments like Lorbrena.
Joanne's work is pivotal in enhancing patient outcomes through innovative data-driven strategies. She specializes in patient journey mapping, which allows her team to analyze and optimize the patient experience from diagnosis through treatment. By leveraging real-world evidence (RWE) and commercial analytics, she translates complex data into actionable insights that inform business strategy and improve clinical trial designs. Her advanced skills in quantitative research, time series analysis, and optimization enable her to tackle the multifaceted challenges of oncology data science.
Fluent in several programming languages, including SAS and SPSS, Joanne is adept at employing sophisticated statistical methodologies to derive meaningful conclusions from large datasets. Her competitive intelligence acumen further positions her as a leader in identifying market trends and opportunities within the oncology landscape. As she continues to drive innovation at Pfizer, Joanne remains committed to advancing the field of oncology through data science, ultimately contributing to better therapeutic outcomes for patients.
